Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Siroquine (JP001) with Chemoradiation for Newly Diagnosed Glioblastoma
NCT03008148Phase 3Unknown
- Sponsor
- Johnpro Biotech Inc.
- Start
- Oct 2018
- Primary completion
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of sirolimus + hydroxychloroquine in glioblastoma (GBM), sponsored by Johnpro Biotech Inc.. Status: unknown.
02
Drugs
sirolimus + hydroxychloroquine
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT03008148.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03008148.